Crc clinical trials

Explore recruiting crc clinical trials.

Recruiting crc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Crc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, randomised, open label, multicentre study to evaluate efficacy and safety of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with peritoneal carcinomatosis from colorectal carcinoma following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Netherlands, Norway, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

Germany, France, Czechia, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)

Spain, Greece, Italy, France, Czechia, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Open label, multicenter dose-escalation and cohort-expansion phase I/IIA trial of STC-1010, an immunotherapy, in patients with unresectable locally advanced or metastatic colorectal cancer (CRC) - BreAK CRC trial (BreAK for Brenus Anti-cancer).

France, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

Italy, Denmark, Spain, Sweden, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, Multicenter, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Crc trials by city

Crc in Toronto Crc in Vancouver Crc in Montreal Crc in Calgary Crc in Edmonton Crc in Ottawa Crc in Winnipeg Crc in Quebec City Crc in Hamilton Crc in Kitchener Crc in London Crc in Halifax Crc in New York Crc in Los Angeles Crc in Chicago Crc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease